financetom
Business
financetom
/
Business
/
World Kinect Q2 revenue falls 18%, misses estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
World Kinect Q2 revenue falls 18%, misses estimates
Jul 31, 2025 2:09 PM

Overview

* World Kinect ( WKC ) Q2 revenue misses analyst expectations, per LSEG data

* Adjusted EPS for Q2 beats analyst estimates, per LSEG data

* Co repurchased $35 mln of common stock and completed UK land fuels sale

Outlook

* Company continues reshaping land business for medium-term performance

* World Kinect ( WKC ) focuses on optimizing finance and accounting operations

* Company committed to building a more focused and efficient operating model

Result Drivers

* AVIATION SEGMENT - Gross profit increased by 8% due to higher contributions from operated airport locations in Europe and business aviation activities

* LAND SEGMENT - Gross profit decreased by 17% due to the sale of the U.K. land business and exit from certain North American operations

* MARINE SEGMENT - Gross profit decreased by 26% due to an unfavorable tax settlement and weaker performance at certain inventory locations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $9.04 $9.32

Revenue bln bln (2

Analysts

)

Q2 Beat $0.59 $0.48 (3

Adjusted Analysts

EPS )

Q2 EPS -$6.06

Q2 Gross $232 mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the oil & gas refining and marketing peer group is "buy."

* Wall Street's median 12-month price target for World Kinect Corp ( WKC ) is $32.00, about 13.5% above its July 30 closing price of $27.67

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US mandates new airline fee disclosure, refund rules
US mandates new airline fee disclosure, refund rules
Apr 24, 2024
WASHINGTON, April 23 (Reuters) - The U.S. Transportation Department is finalizing on Tuesday new rules that require upfront disclosure of airline fees and mandate refunds for delayed baggage or inoperative services like onboard Wi-Fi. The rules, which were nearly three years in the works, will require airlines and ticket agents to tell consumers upfront about baggage or change and cancellation...
Verint Systems Insider Sold Shares Worth $1,051,170, According to a Recent SEC Filing
Verint Systems Insider Sold Shares Worth $1,051,170, According to a Recent SEC Filing
Apr 24, 2024
06:28 AM EDT, 04/24/2024 (MT Newswires) -- Dan Bodner, Director, Chairman & CEO, on April 23, 2024, sold 35,039 shares in Verint Systems ( VRNT ) for $1,051,170. Following the Form 4 filing with the SEC, Bodner has control over a total of 991,748 shares of the company, with 991,748 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1166388/000116638824000055/xslF345X03/wk-form4_1713920501.xml ...
Apr 24, 2024
...
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings
Apr 24, 2024
06:31 AM EDT, 04/24/2024 (MT Newswires) -- Calliditas Therapeutics ( CALT ) said Wednesday that an open-label extension, or OLE, study to its late-stage NefIgArd study showed a treatment response that was consistent with the NefIgArd study's findings. The open-label extension study enrolled 119 patients, 45 of whom were involved in the previous late-stage study and met its endpoints even...
Copyright 2023-2026 - www.financetom.com All Rights Reserved